Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer

Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer

Abstract The prognosis of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) remained unsatisfactory currently, more anti-HER2 agents are needed. Here we report a phase I study that evaluated the safety, activity, and biomarkers of LZM005, a HER2 antibody, used a...

Full description

Bibliographic Details
Main Authors: Cong Xue, Haifeng Li, Herui Yao, Ying Lin, Xin An, Meiting Chen, Riqing Huang, Lu Li, Anqi Hu, Mengqian Ni, Lulu Zhang, Wei Yang, Zhonghui Xu, Su Li, Yanxia Shi
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00501-2

Internet

https://doi.org/10.1038/s41523-022-00501-2

Similar Items